Product Description
Apabetalone has been investigated for the treatment of Diabetes, Atherosclerosis, and Coronary Artery Disease. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Apabetalone)
Mechanisms of Action: BET Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Type 2 Diabetes *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Resverlogix Corp
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Jordan, Saudi Arabia, United Arab Emirates
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Post Acute COVID-19 Syndrome
Phase 2: Kidney Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03160430 |
RVX222-CS-018 | P2 |
Not yet recruiting |
Kidney Failure, Chronic |
2026-11-22 |
12% |
2023-11-16 |
Primary Endpoints |
NCT06590324 |
RVX222-CS-025 | P3 |
Recruiting |
Post Acute COVID-19 Syndrome |
2025-12-30 |
50% |
2025-04-19 |